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Prevalence of dengue transmission has been alarmed by an estimate of 390 million in-
fections per annum. Urban encroachment, ecological disruption and poor sanitation are all
contributory factors of increased epidemiology. Complication however arises from the
fact that dengue virus inherently exists as four different serotypes. Secondary infection is
often manifested in the more severe form, such that antibody-dependent enhancement
(ADE) could aggravate ailment by allowing pre-existing antibodies to form complexes
with infecting viruses as means of intrusion. Consequently, increased viraemic titter and
suppression of antiviral response are observed. Deep concerns are thus expressed in
regards to escalating trend of hospitalisation and mortality rates. In Malaysia, situation is
exacerbated by improper clinical management and pending vector control operations. As
a preparedness strategy against the potential deadly dengue pandemic, the call for
development of a durable and cost-effective dengue vaccine against all infecting sero-
types is intensiﬁed. Even though several vaccine candidates are currently being evaluated
in clinical trials, uncertainties in regards to serotypes interference, incomplete protection
and dose adequacy have been raised. Instead of sole reliance on outsourcing, production
of local vaccine should be considered in coherent to government's efforts to combat
against dengue.1. Introduction
The alarming rise of dengue epidemiology has been high-
lighted to haunt 40% of world population; where disease
severity varies from asymptomatic infection to undifferentiated
dengue fever (DF) or possibly develop into life-threatening
manifestations such as dengue haemorrhagic fever (DHF) and
dengue shock syndrome (DSS) [1]. Classiﬁed under the
Flaviviridae virus family, dengue virus (DENV) presents itself
as a 500 Å single-stranded, positive-sense non-segmented
RNA virus [2]. Size of the virus genome is approximately 10.6
kilo-base pairs (kbp) long; encoding a single polypeptide
which will be processed by serine protease into structural pro-
teins, namely capsid (C); envelope glycoprotein (E); precursormembrane (prM)) and non-structural biomolecules (NS1, 2A,
2B, 3, 4A, 4B and 5) [3]. During assembly, the highly-basic C
protein will encapsidate the viral RNA to form nucleocapsid
particles while prM assists the folding of surface-exposed E
glycoprotein, with both integrated into the lipid bilayer [4].
Hitherto, transmission of the endemic virus has been re-
ported in more than 100 countries. Incidence rate has expanded
by 500-fold, spreading from South-east Asia to Americans and
Western Paciﬁc merely within a-half century [5]. Global
distribution of dengue disease is strongly inﬂuenced by
urbanisation, demographic and environmental factors.
Cumulative concerns are also driven by increased travel of
tourists and military personnel [6]. Based on the 50–100
million of cases reported annually, an average of 500000
patients are hospitalised with DHF and DSS where 22000
deaths are primarily among children [7,8]. Yet, recent study
reported startling estimates of dengue burden that triples past
predictions, where 390 million infections were mapped per
annum [9]. The effect from global warming has also made it
possible for Aedes mosquitoes to survive beyond its current
distribution and further promotes the spread of virus. In fact it
was projected that by 2080s, over 5–6 billion of worldss article under the CC BY-NC-ND license (http://
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change and population growth [10].
2. Pathogenesis
Humans are infected through the bite of Aedes mosquitoes
that usually breed in domestic water containers. Abrupt fever
accompanied by anorexia, headache, myalgia, retro-orbital pain
and occasionally rashes are symptoms of classical DF within 4–
7 days of febrile period [11]. Onset of critical DHF and DSS
usually emerges during time of defervescence where increased
propensity of capillary leakage is observed prior hypovolemic
shock [12]. As infecting virus is being circulated in the
peripheral blood of patients, a mosquito's bite during febrile
viraemic stage would result in disease being transmitted to
another host after an extrinsic incubation period [13]. DHF is
commonly diagnosed with haemorrhagic bleeding,
thrombocytopaenia and increased ﬂuid effusion in addition to
typical DF symptoms; while DSS is presented by weak pulse
and pressure, where profound shock may set in and lead to
death within 12–36 h [11].
Clathrin-mediated endocytosis is deployed as the cell entry
mechanism during initial infection. Upon binding of the viral
particle to the cellular receptor, clathrin-coated pit will capture
the complex and then pinch off into cell cytoplasm [14]. During
secondary infection, complexes are formed between replicating
viruses and non-neutralising antibodies induced by previous
infection or even derived from maternal IgG to usurp Fc-g re-
ceptors as mode of entry [15]. This phenomenon is denoted as
antibody-dependent enhancement (ADE). Upon entry, the ves-
icles move through the endosomes until conformational change
is triggered by acidiﬁcation which ultimately releases the un-
coated single-stranded viral RNA into cytosol [16]. Translation
of viral genetic material proceeds at rough endoplasmic
reticulum (ER) before membrane is invaginated to form
vesicles for RNA replication. Following virus budding into ER
lumen, progeny virions are packed and transported to trans-
Golgi complex for prM cleavage by cellular furin protease
prior releasing mature virions through constitutive secretory
pathway [17].
Feeding of disease carrier presumably introduces DENV
into the bloodstream, where Langerhans cells are targeted fol-
lowed by local replication of virus. Infected dendritic cells then
undergo maturation and migrate towards the lymph nodes to
target monocytes and macrophages [18]. Infection is ampliﬁed
through the dissemination of virus in lymphatic system [11].
In the context of dengue pathogenesis, subversion of host
immunity is achieved by hijacking host cellular machineries
to promote infection. The virus adaption tricks are
summarised as follow: (i) induction of autophagy via
unfolded protein response to trigger production of double
membrane vesicles as viral replication platform; (ii)
mobilisation of triglyceride by lipophagy to produce energy
for viral assembly; and (iii) sequestration of stress granules to
prevent stalling of mRNA translation [19]. Albeit association
of ailment aggravation to ADE still remains elusive,
compiling evidences are now highlighting its cytotoxic
outcome based on increased viraemic titre and/or modulation
of immunosuppressive events to alter conduciveness of local
milieu for viral replication [12]. In fact, it has been proven
that ADE is the strongest risk factor of DHF/DSS
development when severe illness is suffered by seropositivepatients [20]. It was also emphasised that the risk of acquiring
DHF in secondary infections was 40 times signiﬁcantly
higher than primary cases [19].
3. Prevalence and epidemiology
Transmission cycles of DENV are observed from two phe-
nomena: (i) sylvatic cycle of canopy-dwelling Aedes mosquitoes
that infect non-human primates in rain forest habitats of Asia
and Africa; and (ii) infection of human hosts by Aedes aegypti
(A. aegypti) (primary vector) and/or A. albopictus that circulate
in urban and peri-urban environments of tropics [21].
Interestingly, DENV isolates in most urban centres are
evolved from sylvatic progenitors approximately 100–1500
years ago [22]. It is also believed that structural changes of the
domain III of DENV E protein (EDIII) have prompted
adaptation to new peridomestic vectors that led to resurgence
of the arbovirus. Albeit the earliest record of epidemics could
be traced back to 1780–1940, yet, it was the ecological
disruption during World War II that intensiﬁed disease
transmission in South-East Asia and Paciﬁc [21]. In parts of
Central and South American, the collapse of A. aegypti
eradication campaign during early 1970s had set a scene of
re-infestation and hyperendemicity followed due to increased
circulation of viral serotypes into these areas [23]. Escalating
movement of dengue virus into new territories had been
mapped, where geographical spread of different subtypes was
signiﬁcantly noted in the last two decades, particularly in Asia
and Latin America [24]. Contemporary understanding of the
distribution pattern of DENV should be underlined in terms
of providing insights to disease management and clinical
research.4. History of dengue in Malaysia
In Malaysia, onset of dengue infection was dated back in
year 1901 following transmission from Singapore to Penang
[25]. First epidemic outbreak was then alarmed in 1973,
recording a total of 969 cases and 54 deaths [26]. The
condition continued to worsen thereafter, with increasing
disease infestation among urban dwellers throughout the
nation [27]. Taxonomically, the causative agent is an
icosahedral virus that manifests as four distinct subtypes
(DENV1-4) with 65–70% sequence homology [28]. Not
surprisingly, all serotypes were found to be co-circulating in
Malaysia. For instance, DENV1, DENV2 and DENV3 were
identiﬁed in Negeri Sembilan [29], multiple entries of DENV2
and DENV4 in Sarawak [30] while DENV4 dominated the
populated regions of Kuala Lumpur and Selangor [31]. It was
suggested that severity of disease outbreak could be
predicted based on the predominant serotype at one point
[32]. Such correlation was also proven by other ﬁndings,
whereby intense illness was observed in patients suffering
from primary infection of DENV1 or DENV3 whereas
infestation by DENV2 in secondary case would further
aggravate ailment with DHF [33,34]. Generally all gender and
ethnic groups are equally vulnerable to dengue infection. In
South-East Asia, severe DHF/DSS cases are predominant
among paediatric patients aged between 2 and 15 years [35].
However, a shift of disease pattern inclining towards adult
population has been highlighted recently. In Malaysia,
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age group of 13–35 years old [36]. In fact, high dengue IgG
seropositivity (91.6%) had been detected among Malaysian
adults despite of localities [37]. On annual basis, economic
burden of USD $56 million had been allocated as disease
management fees [38]. This is the dengue episode which
causes impact on most health domains, leading to 60% loss
in quality of life (QoL) in the worst scenario [39].
5. Current statistics and disease management
In Malaysia, dengue is perceived as a highly contagious
health threat with escalating trend of infection. The average
number of dengue cases and death tolls had recorded a surge of
14% and 8%, respectively per annum, over the years of 2000–
2010 [40]. Even worse, Malaysia had suffered an increment of
250% infections in 2014 alone as shown in Figure 1 [41,42].
Based on the latest record, a total number of 59866 dengue
cases and 165 deaths had been reported merely within the ﬁrst
half of the year (updated on 6th July 2015). Comparing the
disease trend in Malaysia (see Figure 2 [42]), it is predictable
that dengue will continue to hog nation headlines with record
breaking levels if no effective control operations are enforced.
Situation may only get worse in the upcoming months as
cases usually peak in the spell of wet weather during monsoon
season. With 10000 people contracting the disease every
month, it can progress into more intense scenario as
seroprevalence of dengue antibodies is contributing to high
fatality rate when associated with ADE during secondary
infection. Considering the number of under-reported cases, the
data may not reﬂect the absolute ﬁgure due to low public
awareness and passive surveillance system. This signiﬁes that
dengue episode in Malaysia is under the solemn pressure of
reaching a pandemic level.Figure 1. Statistical number of dengue cases reported within the period 2000
Ministry of Science, Technology and Innovation (MOSTI) [41] and World Hea6. The ‘oldfolk’ remedies
Hitherto, no speciﬁc medication is available for dengue
treatment. Current clinical practices mainly rely on administra-
tion of paracetamol and isotonic intravenous ﬂuids apart from
close monitoring of blood glucose and platelet levels [43].
However, ﬂuid overload could complicate situation when
patient care is not judiciously monitored; which might lead to
circulatory failure in its most severe form. Concern was raised
as high percentage of deaths correlated to ﬂuid overload [44],
thereby reﬂecting the competency gap in clinical management.
Moreover, the lack of vaccine or suitable drug has driven
public's reliance on traditional remedies that are mostly not
scientiﬁcally proven. Common practices include decoction of
tawa–tawa leaves, bitter gourd and preparation of papaya
leaves. Caution must be considered as over-dosage of certain
plant extracts may be toxic. For instance, toxicological studies of
tawa–tawa extract (Euphorbia hirta) had conﬁrmed its geno-
toxic and cytotoxic properties [45,46]. A list of medicinal plants
with tested anti-dengue activity had been summarised by Abd
Kadir et al. [47].
7. Aedes mosquitoes control regimes
Under such circumstances, the only available option to kerb
the disease relies on vector control programmes. Yet, regimes in
practice such as insecticidal treatment and fogging have failed to
produce expected disease containment owing to high cost and
limited effectiveness [48]. Understanding the seasonal cycle of
disease transmission provides a fundamental basis to guarantee
a success of vector control. For instance, fogging can be
scheduled at the peak biting time especially in the advent of
rainy season. Nevertheless, it should be noted that extensive
applications might adversely prompt the emergence of–2014. Data sourced from Malaysian Remote Sensing Agency (ARSM)/
lth Organization Western Paciﬁc Region (WPRO) [42].
Figure 2. A comparative graph showing the trend of dengue infections in Malaysia; translated from Malay to English translation. Diagram modiﬁed from
WPRO [42].
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(a broad spectrum pyrethroid insecticide which is widely
employed for vector control programme in Malaysia) was
questionable when a collection of ﬁeld strains from Kuala
Lumpur had shown to exhibit up to 5.57 folds of resistance [49].
Such preventive practices were also hampered by public's
underestimation of the susceptibility to dengue infection and
the lack of concerted community efforts [50]. Their inattentive
behaviour in maintaining good sanitation (e.g. reduce Aedes
breeding grounds) and reliance on health authority are
community challenges that need serious attention; this possibly
can be overcome upon adopting the Communication for
Behavioural Impact (COMBI) approach by World Health
Organization [51].
A new vector suppression technology (i.e. Release of Insects
with Dominant Lethality, RIDL) was adopted by the Malaysia
government in December 2010. It involved releasing
genetically-modiﬁed (GM) mosquitoes into the uninhabited
forest of Pahang. The sterile male A. aegypti (OX513A) was
manipulated to harbour dominant lethal transgene insertion and
compete with wild-type male for mating. High expression of the
lethal factor in a positive feedback loop would then limit the
survival of transgenics by 95–97% at late-larval or early-pupal
stage [52]. The ultimate aim is to reduce the target population
involved in disease transmission. Albeit the ﬁtness of modiﬁed
strain was not affected in the open ﬁeld settings, the data
obtained was inconclusive to demonstrate vector suppression
as the release site was far beyond their natural habitats
(urbanised area) for mating [48]. Future operational use of the
modiﬁed strain would be supported if similar observation
could be collected as that of the ﬁeld trial in Cayman Islands
[53]. On the other hand, Wolbachia-based biocontrol was
exploited by Australia through transinfection of A. aegypti. In
such approach, dengue transmission is suppressed through
sabotage of vector breeding via cytoplasmic incompatibility
and also shortens virus lifespan by blocking viral replication
in mosquitoes' salivary gland [54]. The Wolbachia invasion
strategy had pulled off a successful ‘proof-of-concept’, where
ﬁxation of bacteria in the wild mosquito population wasobserved after three months [55]. Still, the paradigm of
Wolbachia release requires further monitoring on the direct
test of efﬁcacy. Predictions are made whereby dengue could
mutate to acquire stronger virulence and/or partially escape the
transmission blockage; while evolution of Wolbachia at its
ﬁtness cost is possible since life-shortening property is also
limiting bacterial establishment [56]. So far, ﬁeld trials of
releasing Wolbachia-infected mosquitoes have begun in
dengue endemic areas (i.e. Brazil, Colombia, Indonesia and
Vietnam) where formal assessment of epidemiological
protection can be done [57]. Worthwhile to mention, a lesson
should be learnt from the public backlash against release of
GM mosquitoes in Malaysia. This is because community
engagement is indispensable to gauge support and promote the
implementation of a new programme.
8. Future direction: vaccine development
Waves of dengue vaccine development have increased
dramatically over the decade, aiming to pursue the unmet
medical need of tropical and sub-tropical urban dwellers.
Looking into the state-of-art of vaccine development, competi-
tion on pioneering rights to license an immunoprotective dengue
vaccine has been progressing aggressively among organisations
like Sanoﬁ Pasteur, Walter Reed Army Institute of Research,
Naval Medical Research Center, John Hopkins Bloomberg
School of Public Health and so on. Although live attenuated
vaccines are the most clinically evaluated along the pipeline [58],
potency of other vaccine candidates generated as whole
inactivated virus [59], recombinant subunit protein [60] and
DNA-based vaccine [61] are also undertaking clinical trials.
Despite that, it was predicted that none will be released for
community distribution by year 2015 [62].
While active researches are ongoing, resolving questions on
the ﬂavivirus biology and immunopathogenesis still remain as
the key challenges. Problem to be addressed is even reﬂected
from Sanoﬁ's vaccine candidate. Albeit ChimeriVax-Dengue
(CYD) is advancing to the ﬁnish line, serotypes interference
has been reported. Competition of in vivo viral replication and
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cine was administrated as tetravalent formulation [63]. Imbalance
viral replication among the four monovalent serotypes was
perceived as a threat that could jeopardise the desired level of
immunoprotectivity [64]. The phase 2b clinical trial conducted
in Thailand revealed that CYD did not offer protection against
DENV2 infection even after three doses [65]. The possibility of
antigenic mismatch between CYD2 vaccine design and
DENV2 was ruled in as the factor that could diminish the
overall protection efﬁcacy [66]. Based on the recent phase 3
clinical trials, the vaccine efﬁcacy for serotype 2-speciﬁc still
remained as the lowest [67]. Despite with proven efﬁcacy,
more conclusive data on its tetravalency protection should be
properly assessed in epidemiological settings. Also, it is a
concern if Sanoﬁ can only offer 100 million doses of ﬁrst
vaccine; it is unable to deliver immediate reliefs with 3 billion
of world populaces who are at stake of risk [68].
In terms of subunit vaccine production, dengue E protein has
been the most targeted antigenic determinant. Its structure is
organised into three ectodomains (I–III), serves to assist
attachment and entrance into host cells via receptors like heparin
sulphate [69]. In fact, it is the immunoglobulin-like EDIII that
harbours the receptor binding motif to elicit neutralising
monoclonal antibodies [70]. The selection of EDIII as the
serotype-speciﬁc antigenic determinant was consolidated by
Block et al. [71], stating that other structural proteins (i.e. EDI/II
and prM) were associated with ADE despite having (weak)
neutralisation capacity. The stand-alone stability of domain III
also made it intrinsically different from other parts of the
glycoprotein [72]. In several studies, EDIII was expressed as the
consensus sequence aligned between four DENV serotypes [73–
76], designated as cEDIII. This is justiﬁed based on the
requirement for cross-neutralisation in order to confer full
immunisation against all serotypes. In fact, the mice immuno-
logical data from Leng et al. [73] demonstrated that cEDIII was
able to block viral infections from four serotypes
simultaneously. Due to the fact that wild-type mice are
naturally-resistant to dengue infections, further challenge studies
with non-human primates is thought to be more reliable. How-
ever, recent experimentation by Chen et al. [77] reported
macaques' seroconversion was obtained but unlikely only
against DENV serotype-2. It was explained by the different
epitope recognition site harboured by neutralising antibodies
elicited in different species model. If cEDIII-based antigen is
proven to be useful, it could beneﬁt from being stumbled by
immune interference issue. Moreover, in consideration of virus
mutation and lineage replacement is possible [78,79],
development of a long-term protective vaccine is imperative.
Local vaccine development would have a momentous impact
in Malaysia as, up to date, there are (i) no licensed dengue
vaccine available globally; (ii) no successful vector control re-
gimes to hamper rapid proliferation of A. aegypti especially in
remote areas; and (iii) no published or patented use of local
isolates as tetravalent vaccine candidate. Recording an annual
estimate of USD $238 million economic burden in countries
within South America and South-East Asia, projection is made
that as discovery of dengue vaccine ratchets up, the potential
market could capture an astounding value of USD $2–21 billion
in near future [80,81]. Inundated with escalating dengue outbreaks
that raged through local patients, the protection offered by
established vaccine is anticipated to guard public health, in
line with the government's effort to combat the spread ofdengue through release of genetically-modiﬁed mosquitoes and
reinforced sanitary measures.
9. Conclusion
To battle the upsurge of disease burden implicated in
ambulatory and medical settings, there is an urgent call to
deliver a durable and effective pharmaceutics as no licensed
vaccine is available to date. This is in consideration that dengue
endemic is predominantly suffered by under-developed nations
including Malaysia. Collaborative efforts between dengue vac-
cine research groups and government health agencies are
imperative to make a signiﬁcant contribution in dengue control,
without under-estimating the risk underlying this potentially
fatal global threat.
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